53 related articles for article (PubMed ID: 21894433)
1. Treatment with the Chk1 inhibitor Gö6976 enhances cisplatin cytotoxicity in SCLC cells.
Thompson R; Meuth M; Woll P; Zhu Y; Danson S
Int J Oncol; 2012 Jan; 40(1):194-202. PubMed ID: 21894433
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin and Procaterol Combination in Gastric Cancer? Targeting Checkpoint Kinase 1 for Cancer Drug Discovery and Repurposing by an Integrated Computational and Experimental Approach.
Giridhara Prema S; Chandrasekaran J; Kanekar S; George M; Prasad TSK; Raju R; Dagamajalu S; Balaya RDA
OMICS; 2024 Jan; 28(1):8-23. PubMed ID: 38190280
[TBL] [Abstract][Full Text] [Related]
3. Identification of novel, in vivo active Chk1 inhibitors utilizing structure guided drug design.
Massey AJ; Stokes S; Browne H; Foloppe N; Fiumana A; Scrace S; Fallowfield M; Bedford S; Webb P; Baker L; Christie M; Drysdale MJ; Wood M
Oncotarget; 2015 Nov; 6(34):35797-812. PubMed ID: 26437226
[TBL] [Abstract][Full Text] [Related]
4. The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma.
Walton MI; Eve PD; Hayes A; Henley AT; Valenti MR; De Haven Brandon AK; Box G; Boxall KJ; Tall M; Swales K; Matthews TP; McHardy T; Lainchbury M; Osborne J; Hunter JE; Perkins ND; Aherne GW; Reader JC; Raynaud FI; Eccles SA; Collins I; Garrett MD
Oncotarget; 2016 Jan; 7(3):2329-42. PubMed ID: 26295308
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells.
Parsels LA; Morgan MA; Tanska DM; Parsels JD; Palmer BD; Booth RJ; Denny WA; Canman CE; Kraker AJ; Lawrence TS; Maybaum J
Mol Cancer Ther; 2009 Jan; 8(1):45-54. PubMed ID: 19139112
[TBL] [Abstract][Full Text] [Related]
6. CHK1 Inhibition Is Synthetically Lethal with Loss of B-Family DNA Polymerase Function in Human Lung and Colorectal Cancer Cells.
Rogers RF; Walton MI; Cherry DL; Collins I; Clarke PA; Garrett MD; Workman P
Cancer Res; 2020 Apr; 80(8):1735-1747. PubMed ID: 32161100
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Chk1 stimulates cytotoxic action of platinum-based drugs and TRAIL combination in human prostate cancer cells.
Krkoška M; Paruch K; Šošolíková T; Vázquez-Gómez G; Herůdková J; Novotný J; Ovesná P; Sova P; Hyršlová Vaculová A
Biol Chem; 2024 Jun; 405(6):395-406. PubMed ID: 38452398
[TBL] [Abstract][Full Text] [Related]
8. Entinostat Enhances the Efficacy of Chemotherapy in Small Cell Lung Cancer Through S-phase Arrest and Decreased Base Excision Repair.
Solta A; Boettiger K; Kovács I; Lang C; Megyesfalvi Z; Ferk F; Mišík M; Hoetzenecker K; Aigner C; Kowol CR; Knasmueller S; Grusch M; Szeitz B; Rezeli M; Dome B; Schelch K
Clin Cancer Res; 2023 Nov; 29(22):4644-4659. PubMed ID: 37725585
[TBL] [Abstract][Full Text] [Related]
9. CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs.
Walton MI; Eve PD; Hayes A; Valenti MR; De Haven Brandon AK; Box G; Hallsworth A; Smith EL; Boxall KJ; Lainchbury M; Matthews TP; Jamin Y; Robinson SP; Aherne GW; Reader JC; Chesler L; Raynaud FI; Eccles SA; Collins I; Garrett MD
Clin Cancer Res; 2012 Oct; 18(20):5650-61. PubMed ID: 22929806
[TBL] [Abstract][Full Text] [Related]
10. Tumor Heterogeneity Underlies Differential Cisplatin Sensitivity in Mouse Models of Small-Cell Lung Cancer.
Böttger F; Semenova EA; Song JY; Ferone G; van der Vliet J; Cozijnsen M; Bhaskaran R; Bombardelli L; Piersma SR; Pham TV; Jimenez CR; Berns A
Cell Rep; 2019 Jun; 27(11):3345-3358.e4. PubMed ID: 31189116
[TBL] [Abstract][Full Text] [Related]
11. HMGB1 promotes chemoresistance in small cell lung cancer by inducing PARP1-related nucleophagy.
Shen W; Lyu Q; Yi R; Sun Y; Zhang W; Wei T; Zhang Y; Shi J; Zhang J
J Adv Res; 2023 Dec; ():. PubMed ID: 38159843
[TBL] [Abstract][Full Text] [Related]
12. Impact of fractionated cisplatin and radiation treatment on cell growth and accumulation of DNA damage in two normal cell types differing in origin.
Akuwudike P; López-Riego M; Dehours C; Lundholm L; Wojcik A
Sci Rep; 2023 Sep; 13(1):14891. PubMed ID: 37689722
[TBL] [Abstract][Full Text] [Related]
13. Mutation of the RelA(p65) Thr505 phosphosite disrupts the DNA replication stress response leading to CHK1 inhibitor resistance.
Hunter JE; Campbell AE; Butterworth JA; Sellier H; Hannaway NL; Luli S; Floudas A; Kenneth NS; Moore AJ; Brownridge PJ; Thomas HD; Coxhead J; Taylor L; Leary P; Hasoon MSR; Knight AM; Garrett MD; Collins I; Eyers CE; Perkins ND
Biochem J; 2022 Oct; 479(19):2087-2113. PubMed ID: 36240065
[No Abstract] [Full Text] [Related]
14. Orchestrating smart therapeutics to achieve optimal treatment in small cell lung cancer: recent progress and future directions.
Zhang C; Zhang C; Wang K; Wang H
J Transl Med; 2023 Jul; 21(1):468. PubMed ID: 37452395
[TBL] [Abstract][Full Text] [Related]
15. Network-based survival analysis to discover target genes for developing cancer immunotherapies and predicting patient survival.
He X; Sun X; Shao Y
J Appl Stat; 2021; 48(8):1352-1373. PubMed ID: 35444359
[TBL] [Abstract][Full Text] [Related]
16. Exploitation of the vitamin A/retinoic acid axis depletes ALDH1-positive cancer stem cells and re-sensitises resistant non-small cell lung cancer cells to cisplatin.
MacDonagh L; Santiago RM; Gray SG; Breen E; Cuffe S; Finn SP; O'Byrne KJ; Barr MP
Transl Oncol; 2021 Apr; 14(4):101025. PubMed ID: 33550205
[TBL] [Abstract][Full Text] [Related]
17. Acquired small cell lung cancer resistance to Chk1 inhibitors involves Wee1 up-regulation.
Zhao X; Kim IK; Kallakury B; Chahine JJ; Iwama E; Pierobon M; Petricoin E; McCutcheon JN; Zhang YW; Umemura S; Chen V; Wang C; Giaccone G
Mol Oncol; 2021 Apr; 15(4):1130-1145. PubMed ID: 33320980
[TBL] [Abstract][Full Text] [Related]
18. The clinical significance of CHEK1 in breast cancer: a high-throughput data analysis and immunohistochemical study.
Wu M; Pang JS; Sun Q; Huang Y; Hou JY; Chen G; Zeng JJ; Feng ZB
Int J Clin Exp Pathol; 2019; 12(1):1-20. PubMed ID: 31933717
[TBL] [Abstract][Full Text] [Related]
19. Targeting DNA Replication Stress and DNA Double-Strand Break Repair for Optimizing SCLC Treatment.
Bian X; Lin W
Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31480716
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of the Replication Stress Response Is a Synthetic Vulnerability in SCLC That Acts Synergistically in Combination with Cisplatin.
Nagel R; Avelar AT; Aben N; Proost N; van de Ven M; van der Vliet J; Cozijnsen M; de Vries H; Wessels LFA; Berns A
Mol Cancer Ther; 2019 Apr; 18(4):762-770. PubMed ID: 30872379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
